Pfizer’s agreed takeover Metsera could be in jeopardy, after Novo Nordisk submitted a rival bid to acquire the obesity biotech. Novo Nordisk has offered $56.50 per share in cash for Metsera, reflecting an enterprise value of $6bn, eclipsing the $47.50 per share offer – corresponding to $4.9bn – made by Pfizer in September 2025. Novo is also offering a potential additional $2.5bn if certain milestones are met while Pfizer’s add-on is up to $2.4bn. Novo said the acquisition would be in line with its “long- ...